Mondobiotech Holding AG Company presentation

mondoBIOTECH at a glance
• Headquartered in Stans, Switzerland, mondoBIOTECH holding AG is a public biotech company (SIX Swiss Exchange ticker symbol: RARE) that discovers drugs
– peptides of human origin – for rare and neglected diseases
• The Company identifies effective and safe medicinal product candidates (“MPC”) through redirecting existing and known substances into new
therapeutic indications by utilizing an innovative proprietary methodology called Search&Match. This process searches and analyses peptides and other
biological immuno-modulating substances that are naturally occurring in the human body in order to detect promising candidates for the development
of medicinal products
• Once the Medicinal Product Candidate is recognized the Company partners with the relevant communities or parties and then validates its discovery
through its Community of leading experts in the Orphan Diseases Market (“the Rare Community”)
• The Search&Match engine combined with the knowledge and resources of our worldwide orphan scientific community has so far identified more then 80
MPC’s
• mondoBIOTECH licenses or sells its MPC’s to third parties (such as pharmaceutical or biotechnology companies) and/or collaborate with third parties to
obtain market authorization to commercialize such candidates
10 Orphan drug
designations
in EU and US
8 MPCs Ready for Licensing
19 Patents
granted
81
Medicinal
product
candidates
22 Patent
Families
filed
312 Peptides
to redirect in
rare diseases
3